Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.69 (
botulinum neurotoxin
)
1,901
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The threat posed by botulism, classically a food- and waterborne disease with a high morbidity and mortality, has increased exponentially in an age of bioterrorism. Because
botulinum neurotoxin
(
BoNT
) could be easily disseminated by terrorists using an aerosol or could be used to contaminate the food or water supply, the Centers for Disease Control and Prevention and the National Institute of Allergy and
Infectious Diseases
has classified it as a category A agent. Although clearly the development of a safe and effective mucosal vaccine against this toxin should be a high priority, essentially no studies to date have assessed mucosal immune responses to this disease. To bridge this gap in our knowledge, we immunized mice weekly for 4 wk with nasal doses of
BoNT
type A toxoid and a mutant of cholera toxin termed E112K. We found elevated levels of
BoNT
-specific IgG Abs in plasma and of secretory IgA Abs in external secretions (nasal washes, saliva, and fecal extracts). When mice given nasal
BoNT
vaccine were challenged with 4 x 10(3) LD50 of
BoNT
type A (BoNT/A) via the i.p. route, complete protection was seen, while naive mice given the same dosage died within 2 h. To further confirm the efficacy of this nasal
BoNT
vaccine, an oral LD50 was determined. When mice were given an oral challenge of 5 microg (2 x oral LD50) of progenitor BoNT/A, all immunized mice survived beyond 5 days, while nonimmunized mice did not. The fecal extract samples from nasally vaccinated mice were found to contain neutralizing secretory IgA Abs. Taken together, these results show that nasal BoNT/A vaccine effectively prevents mucosal
BoNT
intoxication.
...
PMID:A novel neurotoxoid vaccine prevents mucosal botulism. 1569 51
Botulism has classically been considered to be a food- and water-borne disease. However, it was recently classified by the US National Institute of Allergy and
Infectious Diseases
(National Institute of Health) and the US Centers for Disease Control and Prevention as a Category A agent. Thus, the botulinum exotoxin, a neurotoxin, could be easily disseminated by bioterrorists through the air-borne route with a high morbidity and mortality rate. In this regard, a high priority should be given to the development of a safe and effective mucosal vaccine to protect against botulinum neurotoxins (BoNTs) since it is well known that the mucosal immune system is the first line of defense against major pathogens. Further, mucosal immunization has been shown to induce both mucosal and systemic immunity to pathogens. By contrast, the current injection-type vaccine only provides protective immunity in the systemic compartment. Clearly, the development of a safe and effective mucosal vaccine against this toxin should be a high priority. In this regard, it has been shown that both nasal and oral immunization approaches have been taken in order to protect from
BoNT
intoxication. In this article, we will discuss the importance of the development of a mucosal vaccine against botulinum and introduce current aspects of
BoNT
mucosal vaccines, which show that they effectively prevent mucosal
BoNT
intoxication.
...
PMID:Mucosal vaccine development for botulinum intoxication. 1728 Apr 77
The 15 proteolytic Clostridium botulinum type B strains, including 3 isolates associated with infant botulism in Japan, were genetically characterized by phylogenetic analysis of boNT/B gene sequences, genotyping, and determination of the boNT/B gene location by using pulsed-field gel electrophoresis (PFGE) for molecular epidemiological analysis of infant botulism in Japan. Strain Osaka05, isolated from a case in 2005, showed a unique boNT/B gene sequence and was considered to be a new
BoNT
/B subtype by phylogenetic analysis. Strain Osaka06, isolated from a case in 2006, was classified as the B2 subtype, the same as strain 111, isolated from a case in 1995. The five isolates associated with infant botulism in the United States were classified into the B1 subtype. Isolates from food samples in Japan were divided into the B1 and the B2 subtypes, although no relation with infant botulism was shown by PFGE genotyping. The results of PFGE and Southern blot hybridization with undigested DNA suggested that the boNT/B gene is located on large plasmids (approximately 150 kbp, 260 kbp, 275 kbp, or 280 kbp) in five strains belonging to three
BoNT
/B subtypes from various sources. The
botulinum neurotoxin
(
BoNT
) of Osaka05 was suggested to have an antigenicity different from the antigenicities of
BoNT
/B1 and
BoNT
/B2 by a sandwich enzyme-linked immunosorbent assay with the recombinant
BoNT
/B-C-terminal domain. We established a multiplex PCR assay for
BoNT
/B subtyping which will be useful for epidemiological studies of type B strains and the
infectious diseases
that they cause.
...
PMID:Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan. 1957 Oct 18
Botulism is a rare but severe neurological disease in man and animals that is caused by botulinum neurotoxins (BoNTs) produced by
Clostridium botulinum
and atypical strains from other
Clostridium
and non-
Clostridium
species. BoNTs are divided into more than seven toxinotypes based on neutralization with specific corresponding antisera, and each toxinotype is subdivided into subtypes according to amino acid sequence variations. Animal species show variable sensitivity to the different
BoNT
toxinotypes. Thereby, naturally acquired animal botulism is mainly due to
BoNT
/C, D and the mosaic variants CD and DC,
BoNT
/CD being more prevalent in birds and
BoNT
/DC in cattle, whereas human botulism is more frequently in the types A, B and E, and to a lower extent, F. Botulism is not a
contagious disease
, since there is no direct transmission from diseased animals or man to a healthy subject. Botulism occurs via the environment, notably from food contaminated with
C. botulinum
spores and preserved in conditions favorable for
C. botulinum
growth and toxin production. The high prevalence of botulism types C, D and variants DC and CD in farmed and wild birds, and to a lower extent in cattle, raises the risk of transmission to human beings. However, human botulism is much rarer than animal botulism, and botulism types C and D are exceptional in humans. Only 15 cases or suspected cases of botulism type C and one outbreak of botulism type D have been reported in humans to date. In contrast, animal healthy carriers of
C. botulinum
group II, such as
C. botulinum
type E in fish of the northern hemisphere, and
C. botulinum
B4 in pigs, represent a more prevalent risk of botulism transmission to human subjects. Less common botulism types in animals but at risk of transmission to humans, can sporadically be observed, such as botulism type E in farmed chickens in France (1998-2002), botulism type B in cattle in The Netherlands (1977-1979), botulism types A and B in horses, or botulism type A in dairy cows (Egypt, 1976). In most cases, human and animal botulisms have distinct origins, and cross transmissions between animals and human beings are rather rare, accidental events. But, due to the severity of this disease, human and animal botulism requires a careful surveillance.
...
PMID:Public Health Risk Associated with Botulism as Foodborne Zoonoses. 3190 8
Intoxication with
botulinum neurotoxin
can occur through various routes. Foodborne botulism results after consumption of food in which
botulinum neurotoxin
-producing clostridia (i.e.,
Clostridium botulinum
or strains of
Clostridium
butyricum
type E or
Clostridium
baratii
type F) have replicated and produced
botulinum neurotoxin
.
Infection
of a wound with
C. botulinum
and in situ production of
botulinum neurotoxin
leads to wound botulism. Colonization of the intestine by neurotoxigenic clostridia, with consequent production of botulinum toxin in the intestine, leads to intestinal toxemia botulism. When this occurs in an infant, it is referred to as infant botulism, whereas in adults or children over 1 year of age, it is intestinal colonization botulism. Predisposing factors for intestinal colonization in children or adults include previous bowel or gastric surgery, anatomical bowel abnormalities, Crohn's disease, inflammatory bowel disease, antimicrobial therapy, or foodborne botulism. Intestinal colonization botulism is confirmed by detection of botulinum toxin in serum and/or stool, or isolation of neurotoxigenic clostridia from the stool, without finding a toxic food. Shedding of neurotoxigenic clostridia in the stool may occur for a period of several weeks. Adult intestinal botulism occurs as isolated cases, and may go undiagnosed, contributing to the low reported incidence of this rare disease.
...
PMID:Adult Intestinal Toxemia Botulism. 3199 91